HEOR and access support for a new product in the treatment of mantle cell lymphoma and Waldenstrom's macroglobulinemia

Written on Monday 1st May 2023


A drug developer from mainland China was entering the US and EU markets for an innovative therapy. OPEN Health partnered with the pharma company to develop HEOR evidence and HTA submission packages for the US, EU5, Canada and Australia.


Our Strategic Market Access and Modeling & Meta-Analysis teams collaborated closely across independent workstreams to ensure a highly creative and efficient multidisciplinary approach that included Strategic Literature Reviews, Indirect Treatment Comparisons and MAICs. Global Value Dossier, AMCP dossiers, trial data analyses. core model and model adaptations, ad board meetings, HTA submissions and publication support.


We used the results to support regulatory decision-making and inform market access and reimbursement discussions around the product in multiple countries.

Working in partnership with our clients, we embrace our different perspectives and strengths to deliver fresh thinking and solutions that make a difference.

Together we can unlock possibilities.

For information about OPEN Health’s services and how we could support you, please get in touch.